Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

E. Gabriela Chiorean; Marco Del Chiaro; Margaret A. Tempero; Mokenge P. Malafa; Al B. Benson; Dana B. Cardin; Jared A. Christensen; Vincent Chung; Brian Czito; Mary Dillhoff; Timothy R. Donahue; Efrat Dotan; Christos Fountzilas; Evan S. Glazer; Jeffrey Hardacre; William G. Hawkins; Kelsey Klute; Andrew H. Ko; John W. Kunstman; Noelle LoConte; Andrew M. Lowy; Ashiq Masood; Cassadie Moravek; Eric K. Nakakura; Amol K. Narang; Lorenzo Nardo; Jorge Obando; Patricio M. Polanco; Sushanth Reddy; Marsha Reyngold; Courtney Scaife; Jeanne Shen; Mark J. Truty; Charles Vollmer; Robert A. Wolff; Brian M. Wolpin; Beth McCullough; Senem Lubin; Susan D. Darlow

doi:10.6004/jnccn.2023.0034

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

E. Gabriela Chiorean
, Marco Del Chiaro
, Margaret A. Tempero
, Mokenge P. Malafa
, Al B. Benson
, Dana B. Cardin
, Jared A. Christensen
, Vincent Chung
, Brian Czito
, Mary Dillhoff
, Timothy R. Donahue
, Efrat Dotan
, Christos Fountzilas
, Evan S. Glazer
, Jeffrey Hardacre
, William G. Hawkins
, Kelsey Klute
, Andrew H. Ko
, John W. Kunstman
, Noelle LoConte

Andrew M. Lowy, Ashiq Masood, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Lorenzo Nardo, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Mark J. Truty, Charles Vollmer, Robert A. Wolff, Brian M. Wolpin, Beth McCullough, Senem Lubin, Susan D. Darlow

Fred Hutchinson Cancer Research Center
University of Colorado Anschutz Medical Campus
University of California at San Francisco
University of South Florida
Northwestern University
Vanderbilt University
University of Michigan, Ann Arbor
City of Hope National Medical Center
Duke University
Ohio State University
University of California at Los Angeles
Roswell Park Comprehensive Cancer Center
University of Tennessee Health Science Center
Case Western Reserve University
Washington University St. Louis
University of Nebraska Medical Center
Yale University
University of Wisconsin-Madison
University of California at San Diego
Indiana University Bloomington
Pancreatic Cancer Action Network
Johns Hopkins University
University of California at Davis
UT Southwestern Simmons Comprehensive Cancer Center
University of Alabama at Birmingham
Memorial Sloan-Kettering Cancer Center
University of Utah
Stanford University
Mayo Clinic
University of Pennsylvania
University of Texas MD Anderson Cancer Center
Dana-Farber Cancer Institute
National Comprehensive Cancer Network

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Abstract

Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.

Original language	English
Pages (from-to)	753-782
Number of pages	30
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	21
Issue number	7
DOIs	https://doi.org/10.6004/jnccn.2023.0034
State	Published - Jul 2023

Keywords

Adenocarcinoma/diagnosis
Ampulla of Vater
Common Bile Duct Neoplasms/diagnosis
Duodenal Neoplasms/diagnosis
Humans
Pancreatic Neoplasms

Access to Document

10.6004/jnccn.2023.0034

Cite this

Chiorean, E. G., Chiaro, M. D., Tempero, M. A., Malafa, M. P., Benson, A. B., Cardin, D. B., Christensen, J. A., Chung, V., Czito, B., Dillhoff, M., Donahue, T. R., Dotan, E., Fountzilas, C., Glazer, E. S., Hardacre, J., Hawkins, W. G., Klute, K., Ko, A. H., Kunstman, J. W., ... Darlow, S. D. (2023). Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 21(7), 753-782. https://doi.org/10.6004/jnccn.2023.0034

@article{1fa4253365fd445bae8d17e3f527fde3,

title = "Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology",

abstract = "Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.",

keywords = "Adenocarcinoma/diagnosis, Ampulla of Vater, Common Bile Duct Neoplasms/diagnosis, Duodenal Neoplasms/diagnosis, Humans, Pancreatic Neoplasms",

author = "Chiorean, \{E. Gabriela\} and Chiaro, \{Marco Del\} and Tempero, \{Margaret A.\} and Malafa, \{Mokenge P.\} and Benson, \{Al B.\} and Cardin, \{Dana B.\} and Christensen, \{Jared A.\} and Vincent Chung and Brian Czito and Mary Dillhoff and Donahue, \{Timothy R.\} and Efrat Dotan and Christos Fountzilas and Glazer, \{Evan S.\} and Jeffrey Hardacre and Hawkins, \{William G.\} and Kelsey Klute and Ko, \{Andrew H.\} and Kunstman, \{John W.\} and Noelle LoConte and Lowy, \{Andrew M.\} and Ashiq Masood and Cassadie Moravek and Nakakura, \{Eric K.\} and Narang, \{Amol K.\} and Lorenzo Nardo and Jorge Obando and Polanco, \{Patricio M.\} and Sushanth Reddy and Marsha Reyngold and Courtney Scaife and Jeanne Shen and Truty, \{Mark J.\} and Charles Vollmer and Wolff, \{Robert A.\} and Wolpin, \{Brian M.\} and Beth McCullough and Senem Lubin and Darlow, \{Susan D.\}",

year = "2023",

month = jul,

doi = "10.6004/jnccn.2023.0034",

language = "English",

volume = "21",

pages = "753--782",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Harborside Press",

number = "7",

}

Chiorean, EG, Chiaro, MD, Tempero, MA, Malafa, MP, Benson, AB, Cardin, DB, Christensen, JA, Chung, V, Czito, B, Dillhoff, M, Donahue, TR, Dotan, E, Fountzilas, C, Glazer, ES, Hardacre, J, Hawkins, WG, Klute, K, Ko, AH, Kunstman, JW, LoConte, N, Lowy, AM, Masood, A, Moravek, C, Nakakura, EK, Narang, AK, Nardo, L, Obando, J, Polanco, PM, Reddy, S, Reyngold, M, Scaife, C, Shen, J, Truty, MJ, Vollmer, C, Wolff, RA, Wolpin, BM, McCullough, B, Lubin, S & Darlow, SD 2023, 'Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 21, no. 7, pp. 753-782. https://doi.org/10.6004/jnccn.2023.0034

TY - JOUR

T1 - Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

AU - Chiorean, E. Gabriela

AU - Chiaro, Marco Del

AU - Tempero, Margaret A.

AU - Malafa, Mokenge P.

AU - Benson, Al B.

AU - Cardin, Dana B.

AU - Christensen, Jared A.

AU - Chung, Vincent

AU - Czito, Brian

AU - Dillhoff, Mary

AU - Donahue, Timothy R.

AU - Dotan, Efrat

AU - Fountzilas, Christos

AU - Glazer, Evan S.

AU - Hardacre, Jeffrey

AU - Hawkins, William G.

AU - Klute, Kelsey

AU - Ko, Andrew H.

AU - Kunstman, John W.

AU - LoConte, Noelle

AU - Lowy, Andrew M.

AU - Masood, Ashiq

AU - Moravek, Cassadie

AU - Nakakura, Eric K.

AU - Narang, Amol K.

AU - Nardo, Lorenzo

AU - Obando, Jorge

AU - Polanco, Patricio M.

AU - Reddy, Sushanth

AU - Reyngold, Marsha

AU - Scaife, Courtney

AU - Shen, Jeanne

AU - Truty, Mark J.

AU - Vollmer, Charles

AU - Wolff, Robert A.

AU - Wolpin, Brian M.

AU - McCullough, Beth

AU - Lubin, Senem

AU - Darlow, Susan D.

PY - 2023/7

Y1 - 2023/7

N2 - Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.

AB - Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.

KW - Adenocarcinoma/diagnosis

KW - Ampulla of Vater

KW - Common Bile Duct Neoplasms/diagnosis

KW - Duodenal Neoplasms/diagnosis

KW - Humans

KW - Pancreatic Neoplasms

UR - https://www.scopus.com/pages/publications/85164383189

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:001081197400009&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2023.0034

DO - 10.6004/jnccn.2023.0034

M3 - Article

C2 - 37433437

SN - 1540-1405

VL - 21

SP - 753

EP - 782

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 7

ER -

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this